Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepwise lipid-lowering therapy after myocardial infarction to assess unmet LDL-C targets in very high-risk patients
NL-OMON55816Phase 4Active, not recruiting
- Sponsor
- WorldCare
- Start
- Jan 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alirocumab, ezetimibe, atorvastatin and rosuvastatin in hypercholesterolemia and hyperlipidemia, sponsored by WorldCare. Started Jan 2019; status: active, not recruiting.
02
Drugs
alirocumabezetimibeatorvastatinrosuvastatin
03
Conditions
hypercholesterolemiahyperlipidemia
Beyond the preview
Go deeper on NL-OMON55816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55816.